Olanzapine

Source: Wikipedia, the free encyclopedia.
(Redirected from
Zyprexa
)

Olanzapine
Clinical data
Trade namesZyprexa, Zypine, others[1]
AHFS/Drugs.comMonograph
MedlinePlusa601213
License data
Pregnancy
category
  • AU: C
Routes of
administration		By mouth, intramuscular injection
Drug classAtypical antipsychotic
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability60–65%[5][6][7]
Protein binding93%[8]
MetabolismLiver (direct glucuronidation and CYP1A2 mediated oxidation)
Elimination half-life33 hours, 51.8 hours (elderly)[8]
ExcretionUrine (57%; 7% as unchanged drug), faeces (30%)[8][9]
Identifiers
  • 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
JSmol)
Melting point195 °C (383 °F)
Solubility in waterPractically insoluble in water mg/mL (20 °C)
  • CN1CCN(CC1)C/2=N/c4ccccc4Nc3sc(C)cc\23
  • InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3 checkY
  • Key:KVWDHTXUZHCGIO-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Olanzapine, sold under the brand name Zyprexa among others, is an

injection into a muscle.[10]

Common side effects include

serotonin receptors.[10]

Olanzapine was patented in 1991 and approved for medical use in the

generic medication.[10] In 2021, it was the 164th most commonly prescribed medication in the United States, with more than 3 million prescriptions.[12][13] Eli Lilly also markets olanzapine in a fixed-dose combination with fluoxetine as olanzapine/fluoxetine (Symbyax).[14] It is on the World Health Organization's List of Essential Medicines.[15]

Medical uses

It is approved by FDA for the following indications:

In the United Kingdom and Australia, it is approved for schizophrenia, moderate to severe manic episodes, alone, or in combination with lithium or valproate and the short-term treatment of acute manic episodes associated with Bipolar I Disorder.[19][20]

Schizophrenia

The first-line psychiatric treatment for schizophrenia is antipsychotic medication.[21] Olanzapine appears to be effective in reducing symptoms of schizophrenia, treating acute exacerbations, and treating early-onset schizophrenia.[22][23][24][25] The usefulness of maintenance therapy, however, is difficult to determine, as more than half of people in trials quit before the 6-week completion date.[26] Treatment with olanzapine (like clozapine) may result in increased weight gain and increased glucose and cholesterol levels when compared to most other second-generation antipsychotic drugs used to treat schizophrenia.[23][27]

Bipolar disorder

Olanzapine is recommended by the National Institute for Health and Care Excellence as a first-line therapy for the treatment of acute mania in bipolar disorder.[28] Other recommended first-line treatments are aripiprazole, haloperidol, quetiapine, and risperidone.[29] It is recommended in combination with fluoxetine as a first-line therapy for acute bipolar depression, and as a second-line treatment by itself for the maintenance treatment of bipolar disorder.[28]

The Network for Mood and Anxiety Treatments recommends olanzapine as a first-line maintenance treatment in bipolar disorder and the combination of olanzapine with fluoxetine as second-line treatment for bipolar depression.[30]

A review on the efficacy of olanzapine as maintenance therapy in people with bipolar disorder was published by in 2006.[31] A 2014 meta-analysis concluded that olanzapine with fluoxetine was the most effective among nine treatments for bipolar depression included in the analysis.[32]

Specific populations

Pregnancy and lactation

Olanzapine is associated with the highest placental exposure of any atypical antipsychotic.

neural tube defects (e.g. spina bifida).[34][35] Breastfeeding in women taking olanzapine is advised against because olanzapine is secreted in breast milk, with one study finding that the exposure to the infant is about 1.8% that of the mother.[8]

Elderly

Citing an increased risk of

black box warning for increased risk of death in elderly patients. It is not approved for use in patients with dementia-related psychosis.[36] A BBC investigation in June 2008 found that this advice was being widely ignored by British doctors.[37] Evidence suggested that the elderly are more likely to experience weight gain on olanzapine compared to aripiprazole and risperidone.[38]

Adverse effects

See also: List of adverse effects of olanzapine

The principal side effect of olanzapine is weight gain, which may be profound in some cases and/or associated with derangement in blood-lipid and blood-sugar profiles (see section metabolic effects). A 2013 meta-analysis of the efficacy and tolerance of 15 antipsychotic drugs (APDs) found that it had the highest propensity for causing weight gain out of the 15 APDs compared with an SMD of 0.74.[22] Extrapyramidal side effects, although potentially serious, are infrequent to rare from olanzapine,[39] but may include tremors and muscle rigidity.

Aripiprazole, asenapine, clozapine, quetiapine and olanzapine, in comparison to other antipsychotic drugs, are less frequently associated with hyperprolactinaemia. Although these drugs can cause transient or sustained hyperprolactinaemia, the risk is much lower. Owing to its partial dopaminergic agonist effect, aripiprazole is likely to reduce prolactin levels and, in some patients, can cause hypoprolactinaemia.[40] Although olanzapine causes an early dose-related rise in prolactin, this is less frequent and less marked than that seen with haloperidol, and is usually transient. A rise in prolactin is seen in about half of patients on olanzapine compared to over 90% of those taking risperidone, and enduring increases were less frequent in those taking olanzapine.[41]

It is not recommended to be used by IM injection in acute myocardial infarction, bradycardia, recent heart surgery, severe hypotension, sick sinus syndrome, and unstable angina.[42]

Several patient groups are at a heightened risk of side effects from olanzapine and antipsychotics in general. Olanzapine may produce nontrivial

diabetes mellitus. Likewise, the elderly are at a greater risk of falls and accidental injury. Young males appear to be at heightened risk of dystonic reactions, although these are relatively rare with olanzapine. Most antipsychotics, including olanzapine, may disrupt the body's natural thermoregulatory systems, thus permitting excursions to dangerous levels when situations (exposure to heat, strenuous exercise) occur.[8][9][43][44][45]

Other side effects include galactorrhea, amenorrhea, gynecomastia, and erectile dysfunction (impotence).[46]

Drug-induced OCD

Main article: Obsessive–compulsive disorder § Drug-induced OCD

Many different types of medication can create or induce pure obsessive-compulsive disorder (OCD) in patients who have never had symptoms before. A new chapter about OCD in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (2013) now specifically includes drug-induced OCD.

Metabolic effects

The US

insulin sensitivity,[56][57] though one 3-week study seems to refute this.[58] It may also increase triglyceride levels.[50]

Despite weight gain, a large multicenter, randomized National Institute of Mental Health study found that olanzapine was better at controlling symptoms because patients were more likely to remain on olanzapine than the other drugs.[59] One small, open-label, nonrandomized study suggests that taking olanzapine by orally dissolving tablets may induce less weight gain,[60] but this has not been substantiated in a blinded experimental setting.

Post-injection delirium/sedation syndrome

Postinjection delirium/sedation syndrome (PDSS) is a rare syndrome that is specific to the long-acting injectable formulation of olanzapine, olanzapine

paliperidone palmitate), which do not appear to carry the same risk.[61] PDSS is characterized by symptoms of delirium (e.g. confusion, difficulty speaking, and uncoordinated movements) and sedation.[61] Most people with PDSS exhibit both delirium and sedation (83%).[61] Although less specific to PDSS, a majority of cases (67%) involved a feeling of general discomfort.[61] PDSS may occur due to accidental injection and absorption of olanzapine pamoate into the bloodstream, where it can act more rapidly, as opposed to slowly distributing out from muscle tissue.[61] Using the proper, intramuscular-injection technique for olanzapine pamoate helps to decrease the risk of PDSS, though it does not eliminate it entirely.[61] This is why the FDA advises that people who are injected with olanzapine pamoate be watched for 3 hours after administration, in the event that PDSS occurs.[61]

Animal toxicology

Olanzapine has demonstrated carcinogenic effects in multiple studies when exposed chronically to female mice and rats, but not male mice and rats. The tumors found were in either the liver or mammary glands of the animals.[62]

Discontinuation

The

discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse.[63] Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite.[64] Other symptoms may include restlessness, increased sweating, and trouble sleeping.[64] Less commonly, vertigo, numbness, or muscle pains may occur.[64] Symptoms generally resolve after a short time.[64]

Tentative evidence indicates that discontinuation of antipsychotics can result in psychosis, as a temporary withdrawal symptom.[65] It may also result in reoccurrence of the condition that is being treated.[66] Rarely, tardive dyskinesia can occur when the medication is stopped.[64]

Overdose

Symptoms of an overdose include

post mortem, with concentrations up to 5200 ng/mL recorded (though this might represent confounding by dead tissue, which may release olanzapine into the blood upon death).[68] No specific antidote for olanzapine overdose is known, and even physicians are recommended to call a certified poison control center for information on the treatment of such a case.[67]
Olanzapine is considered moderately toxic in overdose, more toxic than quetiapine, aripiprazole, and the
tricyclic antidepressants.[33]

Interactions

Drugs or agents that increase the activity of the enzyme CYP1A2, notably tobacco smoke, may significantly increase hepatic first-pass clearance of olanzapine; conversely, drugs that inhibit CYP1A2 activity (examples: ciprofloxacin, fluvoxamine) may reduce olanzapine clearance.[69] Carbamazepine, a known enzyme inducer, has decreased the concentration/dose ratio of olanzapine by 33% compared to olanzapine alone.[68] Another enzyme inducer, ritonavir, has also been shown to decrease the body's exposure to olanzapine, due to its induction of the enzymes CYP1A2 and uridine 5'-diphospho-glucuronosyltransferase (UGT).[68] Probenecid increases the total exposure (area under the curve) and maximum plasma concentration of olanzapine.[68] Although olanzapine's metabolism includes the minor metabolic pathway of CYP2D6, the presence of the CYP2D6 inhibitor fluoxetine does not have a clinically significant effect on olanzapine's clearance.[68]

Pharmacology

Pharmacodynamics

See also: Atypical antipsychotic § Pharmacodynamics, and Antipsychotic § Comparison of medications

Olanzapine was first discovered while searching for a chemical analog of clozapine that would not require hematological monitoring. Investigation on a series of thiophene isosteres on 1 of the phenyl rings in clozapine, a thienobenzodiazepine analog (olanzapine) was discovered.[70]

Olanzapine[71]
Site Ki (nM) Action Ref
SERTTooltip Serotonin transporter ≥3,676 ND [71][72]
NETTooltip Norepinephrine transporter >10,000 ND [71]
DATTooltip Dopamine transporter >10,000 ND [71]
5-HT1A 2,063–2,720 Antagonist [73][74]
5-HT1B 509–660 ND [71][74]
5-HT1D 540–1,582 ND [71][74]
5-HT1E 2,010–2,408 ND [71][74]
5-HT1F 310 ND [74]
5-HT2A 1.32–24.2 Inverse agonist [75][76]
5-HT2B 11.8–12.0 Inverse agonist [77][78]
5-HT2C 6.4–29 Inverse agonist [76][78]
5-HT3 202 Antagonist [71]
5-HT5A 1,212 Full Agonist [71]
5-HT6 6.0–42 Antagonist [71][79]
5-HT7 105–365 Antagonist [71][80]
α1A 109–115 Antagonist [71][73]
α1B 263 Antagonist [71]
α2A 192–470 Antagonist [74][80]
α2B 82–180 Antagonist [73][74]
α2C 29–210 Antagonist [73][74]
β1 >10,000 ND [71][74]
β2 >10,000 ND [71][74]
D1
 35–118 Antagonist [76][80]
D2
 3.00–106 Antagonist [81][82]
D2L
 31–38 Antagonist [74][76]
D2S
 21–52 Antagonist [74][83]
D3
 7.8–91 Antagonist [81][82]
D4
 1.6–50 Antagonist [81][72]
D4.2
 17–102 Antagonist [84][85]
D4.4
 21–60 Antagonist [83]
D5
 74–90 Antagonist [71][76]
H1 0.65–4.9 Inverse agonist [71][74]
H2 44 Antagonist [71]
H3 3,713 Antagonist [71]
H4 >10,000 Antagonist [71]
M1 2.5–73 Antagonist [86][87]
M2 48–622 Antagonist [79]
M3 13–126 Antagonist [78][79]
M4 10–350 Antagonist [79][86]
M5 6.0–82 Antagonist [79][86]
σ1 >5,000 ND [74]
σ2 ND ND ND
Opioid >10,000 ND [74]
nAChTooltip Nicotinic acetylcholine receptor >10,000 ND [71]
NMDA
(PCP)		 >10,000 ND [71]
VDCC
Tooltip Voltage-dependent calcium channel		 >10,000 ND [71][74]
VGSCTooltip Voltage-gated sodium channel >5,000 ND [74]
hERG
Tooltip Human Ether-à-go-go-Related Gene		 6,013 Blocker [88]
Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site. All data are for human cloned proteins, except H3 (guinea pig), σ1 (guinea pig), opioid (rodent), NMDA/PCP (rat), VDCC, and VGSC.[71]

Olanzapine has a higher affinity for

5-HT2A serotonin receptors than D2 dopamine receptors, which is a common property of most atypical antipsychotics, aside from the benzamide antipsychotics such as amisulpride along with the nonbenzamides aripiprazole, brexpiprazole, blonanserin, cariprazine, melperone, and perospirone
.

In one study D2 receptor occupancy was 60% with low-dose olanzapine (5 mg/day) and occupancy with high dose at 83% (20 mg/day).[89] In the usual clinical dose range of 10–20 mg/day, D2 receptor occupancy varied from 71% to 80%.[90][91]

Olanzapine occupancy at 5-HT2A receptor are high at all doses (5 mg to 20 mg). It is reported that 5 mg dose of olanzapine produced a mean occupancy of 85% at 5 mg, 88% at 10 mg, and 93% at 20 mg dose .[92]

Olanzapine had the highest affinity of any second-generation antipsychotic towards the P-glycoprotein in one in vitro study.[93] P-glycoprotein transports a myriad of drugs across a number of different biological membranes (found in numerous body systems) including the blood–brain barrier (a semipermeable membrane that filters the contents of blood prior to it reaching the brain); P-GP inhibition could mean that less brain exposure to olanzapine results from this interaction with the P-glycoprotein.[94] A relatively large quantity of commonly encountered foods and medications inhibit P-GP, and pharmaceuticals fairly commonly are either substrates of P-GP, or inhibit its action; both substrates and inhibitors of P-GP effectively increase the permeability of the blood–brain barrier to P-GP substrates and subsequently increase the central activity of the substrate, while reducing the local effects on the GI tract. The mediation of olanzapine in the central nervous system by P-GP means that any other substance or drug that interacts with P-GP increases the risk for toxic accumulations of both olanzapine and the other drug.[95]

Olanzapine is a potent antagonist of the muscarinic M3 receptor,[96] which may underlie its diabetogenic side effects.[97][98] Additionally, it also exhibits a relatively low affinity for serotonin 5-HT1, GABAA, β-adrenergic receptors, and benzodiazepine binding sites.[39][99]

Although antagonistic effects of olanzapine at 5-HT2C alone is not associated with weight gain, olanzapine antagonism at histaminergic H1, and muscarinic M3 receptors have been implicated in weight gain.[70][100][101]

The mode of action of olanzapine's antipsychotic activity is unknown. It may involve antagonism of

muscarinic acetylcholine receptors is associated with anticholinergic side effects such as dry mouth and constipation; in addition, it may suppress or reduce the emergence of extrapyramidal effects for the duration of treatment, but it offers no protection against the development of TD. In common with other second-generation (atypical) antipsychotics, olanzapine poses a relatively low risk of extrapyramidal side effects including TD, due to its higher affinity for the 5HT2A receptor over the D2 receptor.[102]

Antagonizing H1 histamine receptors causes sedation and may cause weight gain, although antagonistic actions at serotonin 5-HT2C and dopamine D2 receptors have also been associated with weight gain and appetite stimulation.[103]

Pharmacokinetics

Metabolism

Olanzapine is metabolized by the cytochrome P450 (CYP) system; principally by isozyme 1A2 (CYP1A2) and to a lesser extent by CYP2D6. By these mechanisms, more than 40% of the oral dose, on average, is removed by the hepatic first-pass effect.[39] Clearance of olanzapine appears to vary by sex; women have roughly 25% lower clearance than men.[68] Clearance of olanzapine also varies by race; in self-identified African Americans or Blacks, olanzapine's clearance was 26% higher.[68] A difference in the clearance is not apparent between individuals identifying as Caucasian, Chinese, or Japanese.[68] Routine, pharmacokinetic monitoring of olanzapine plasma levels is generally unwarranted, though unusual circumstances (e.g. the presence of drug–drug interactions) or a desire to determine if patients are taking their medicine may prompt its use.[68]

Chemistry

Olanzapine is unusual in having four well-characterised crystalline

polymorphs and many hydrated forms.[104]

Chemical synthesis

The preparation of olanzapine was first disclosed in a series of patents from

methylpiperazine in a mixture of dimethyl sulfoxide and toluene as solvent to produce the drug.[105]

Society and culture

Zyprexa (olanzapine) 10 mg tablets (AU)

Legal status

Olanzapine is approved by the US FDA for:

  • Treatment—in combination with fluoxetine—of depressive episodes associated with bipolar disorder (December 2003).[106]
  • Long-term treatment of bipolar I disorder (January 2004).[107][108]
  • Long-term treatment—in combination with fluoxetine—of resistant depression (March 2009)[109]
  • Oral formulation: acute and maintenance treatment of schizophrenia in adults, acute treatment of manic or mixed episodes associated with bipolar I disorder (monotherapy and in combination with
    sodium valproate
    )
  • Intramuscular formulation: acute agitation associated with schizophrenia and bipolar I mania in adults
  • Oral formulation combined with fluoxetine: treatment of acute depressive episodes associated with bipolar I disorder in adults, or treatment of acute, resistant depression in adults[110]
  • Treatment of the manifestations of psychotic disorders (September 1996[111] – March 2000).[112]
  • Short-term treatment of acute manic episodes associated with bipolar I disorder (March 2000)[112]
  • Short-term treatment of schizophrenia instead of the management of the manifestations of psychotic disorders (March 2000)[112]
  • Maintaining treatment response in schizophrenic patients who had been stable for about eight weeks and were then followed for a period of up to eight months (November 2000)[112]

The drug became

generic in 2011. Sales of Zyprexa in 2008 were $2.2 billion in the US and $4.7 billion worldwide.[113]

Controversy and litigation

Eli Lilly has faced many lawsuits from people who claimed they developed diabetes or other diseases after taking Zyprexa, as well as by various governmental entities, insurance companies, and others. Lilly produced a large number of documents as part of the discovery phase of this litigation, which started in 2004; the documents were ruled to be confidential by a judge and placed under seal, and later themselves became the subject of litigation.[114]

In 2006, Lilly paid $700 million to settle around 8,000 of these lawsuits,[115] and in early 2007, Lilly settled around 18,000 suits for $500 million, which brought the total Lilly had paid to settle suits related to the drug to $1.2 billion.[116][117]

A December 2006

New York Times article based on leaked company documents concluded that the company had engaged in a deliberate effort to downplay olanzapine's side effects.[116][118] The company denied these allegations and stated that the article had been based on cherry-picked documents.[116][117] The documents were provided to the Times by Jim Gottstein, a lawyer who represented mentally ill patients, who obtained them from a doctor, David Egilman, who was serving as an expert consultant on the case.[114] After the documents were leaked to online peer-to-peer, file-sharing networks by Will Hall and others in the psychiatric survivors movement, who obtained copies,[119] in 2007 Lilly filed a protection order to stop the dissemination of some of the documents, which Judge Jack B. Weinstein of the Brooklyn Federal District Court granted. Judge Weinstein also criticized the New York Times reporter, Gottstein, and Egilman in the ruling.[114] The Times of London also received the documents and reported that as early as 1998, Lilly considered the risk of drug-induced obesity to be a "top threat" to Zyprexa sales.[117] On 9 October 2000, senior Lilly research physician Robert Baker noted that an academic advisory board to which he belonged was "quite impressed by the magnitude of weight gain on olanzapine and implications for glucose."[117]

Lilly had threatened Egilman with criminal contempt charges regarding the documents he took and provided to reporters; in September 2007, he agreed to pay Lilly $100,000 in return for the company's agreement to drop the threat of charges.[120]

In September 2008, Judge Weinstein issued an order to make public Lilly's internal documents about the drug in a different suit brought by insurance companies, pension funds, and other payors.[114]

In March 2008, Lilly settled a suit with the state of Alaska,[121] and in October 2008, Lilly agreed to pay $62 million to 32 states and the District of Columbia to settle suits brought under state consumer protection laws.[120]

In 2009, Eli Lilly pleaded guilty to a US federal criminal misdemeanor charge of illegally marketing Zyprexa for off-label use and agreed to pay $1.4 billion. The settlement announcement stated "Eli Lilly admits that between September 1999 and March 31, 2001, the company promoted Zyprexa in elderly populations as treatment for dementia, including Alzheimer's dementia. Eli Lilly has agreed to pay a $515 million criminal fine and to forfeit an additional $100 million in assets."[122][123]

The outcomes described here, and their legal ramifications, were fueled by motions and appeals that were not resolved until 2010.[124] In 2021, Gottstein summarized this tangle of legal activities, and their impact on the political landscape of psychiatry and antipsychiatry in the US, in The Zyprexa Papers.[125]

Brand names

Olanzapine is generic and available under many brand names worldwide.[1]

List of
brand names for olanzapine[1]
A Aedon, Alonzap, Amulsin, Anzap, Anzatric, Anzorin, Apisco, Apo-Olanzapine, Apo-Olanzapine ODT, Apsico, Arenbil, Arkolamyl
B Benexafrina, Bloonis
C Caprilon, Cap-Tiva, Clingozan
D Deprex, Domus, Dopin
E Egolanza, Elynza, Emzypine, Epilanz-10, Exzapine
F Fontanivio, Fordep
G
H
I Irropia
J Jolyon-MD
K Kozylex
L Lanopin, Lanzapine, Lanzep, Lapenza, Lapozan, Lazap, Lazapir, Lazapix, Lezapin-MD, Lopez
M Meflax, Midax, Medizapin
N Niolib, Norpen Oro, Nykob, Nyzol
O Oferta, Oferta-Sanovel, Olace, Oladay, Oladay-F, Olaffar, Olan, Olanap, Olancell, Olandix, Olandoz, Olandus, Olankline, Olanpax, Olanstad, Olanza, Olanza Actavis, Olanza Actavis ODT, Olanzalet, Olanzalux, Olanzamed, Olanzapin 1A Pharma, Olanzapin AbZ, Olanzapin Accord, Olanzapin Actavis, Olanzapin AL, Olanzapin Apotex, Olanzapin Aristo, Olanzapin axcount, Olanzapin beta, Olanzapin Bluefish, Olanzapin Cipla, Olanzapin easypharm, Olanzapin Egis, Olanzapin G.L., Olanzapin Genera, Olanzapin Genericon, Olanzapin Helvepharm, Olanzapin Hennig, Olanzapin Heumann, Olanzapin HEXAL, Olanzapin Krka, Olanzapin Lilly, Olanzapin Mylan, Olanzapin Niolib, Olanzapin Orion, Olanzapin PCD, Olanzapin PharmaS, Olanzapin Ranbaxy, Olanzapin ratiopharm, Olanzapin ReplekFarm, Olanzapin Rth, Olanzapin Sandoz, Olanzapin Spirig HC, Olanzapin Stada, Olanzapin SUN, Olanzapin Teva, Olanzapin Viketo, Olanzapin Zentiva, Olanzapina Accord, Olanzapina Actavis, Olanzapina Actavis PTC, Olanzapina Aldal, Olanzapina Almus, Olanzapina Alter, Olanzapina Angenerico, Olanzapina Anipaz, Olanzapina Apotex, Olanzapina APS, Olanzapina Arrowblue, Olanzapina Aspen, Olanzapina Aurobindo, Olanzapina Basi, Olanzapina Bexalabs, Olanzapina Blixie, Olanzapina Bluefish, Olanzapina Bluepharma, Olanzapina Cantabria, Olanzapina Ceapharma, Olanzapina Ciclum, Olanzapina Cinfa, Olanzapina Cipla, Olanzapina Combix, Olanzapina Doc Generici, Olanzapina Dr. Reddy's, Olanzapina Eulex, Olanzapina Eurogenerici, Olanzapina Fantex, Olanzapina Farmoz, Olanzapina Flas Pharma Combix, Olanzapina Genedec, Olanzapina Generis, Olanzapina Germed, Olanzapina Glenmark, Olanzapina Green Avet, Olanzapina Helm, Olanzapina Kern Pharma, Olanzapina Krka, Olanzapina La Santé, Olanzapina Labesfal, Olanzapina Leugim, Olanzapina Lilly, Olanzapina LPH, Olanzapina Mabo, Olanzapina Medana, Olanzapina Medis, Olanzapina Medley, Olanzapina Mylan, Olanzapina Nakozap, Olanzapina Nolian, Olanzapina Normon, Olanzapina Ozilormar, Olanzapina Parke-Davis, Olanzapina Pensa, Olanzapina Pensa Pharma, Olanzapina Pharmakern, Olanzapina Polipharma, Olanzapina Polpharma, Olanzapina Qualigen, Olanzapina Ranbaxy, Olanzapina Ratio, Olanzapina Ratiopharm, Olanzapina Reconir, Olanzapina Reddy, Olanzapina Rospaw, Olanzapina Sabacur, Olanzapina Sandoz, Olanzapina Sarb, Olanzapina Stada, Olanzapina Sun, Olanzapina TAD, Olanzapina Technigen, Olanzapina Terapia, Olanzapina Teva, Olanzapina Tevagen, Olanzapina tolife, Olanzapina Torrent, Olanzapina Vegal, Olanzapina Vida, Olanzapina Winthrop, Olanzapina Wynn, Olanzapina Kraz, Olanzapina Zentiva, Olanzapina Zerpi, Olanzapina Zonapir, Olanzapin-Actavis, Olanzapin-CT, Olanzapine 1A Pharma, Olanzapine Accord, Olanzapine Actavis, Olanzapine Adamed, Olanzapine Alter, Olanzapine Alvogen, Olanzapine Apotex, Olanzapine Arrow Génériques, Olanzapine Auro, Olanzapine Aurobindo, Olanzapine Biogaran, Olanzapine Bluefish, Olanzapine CF, Olanzapine Clonmel, Olanzapine Cristers, Olanzapine Dexcel, Olanzapine EG, Olanzapine Egis, Olanzapine Evolugen, Olanzapine Galenicum, Olanzapine Generichealth, Olanzapine Glenmark, Olanzapine GSK, Olanzapine Isomed, Olanzapine Jacobsen, Olanzapine Jubilant, Olanzapine Lekam, Olanzapine Lesvi, Olanzapine Medana, Olanzapine Mylan, Olanzapine Neopharma, Olanzapine Niolib, Olanzapine Nyzol, Olanzapine Odis Mylan, Olanzapine ODT Generichealth, Olanzapine ODT Sanis Health, Olanzapine ODT Teva, Olanzapine ODT-DRLA, Olanzapine Orion, Olanzapine Polpharma, Olanzapine Prasco, Olanzapine Ranbaxy, Olanzapine Ratiopharm, Olanzapine Sandoz, Olanzapine Sanis Health, Olanzapine Sanovel, Olanzapine Stada, Olanzapine Sun, Olanzapine Synthon, Olanzapine Teva, Olanzapine Torrent, Olanzapine Zentiva, Olanzapine Zentiva Lab, Olanzapine Zydus, Olanzapine-DRLA, Olzapine, Olanzia
P Pinaz
Q
R
S
T
U
V
W
X
Y
Z Zyprexa, Zolafren, Zalasta, Zypine

Dosage forms

Olanzapine is marketed in a number of countries, with tablets ranging from 2.5 to 20 mg. Zyprexa (and generic olanzapine) is available as an orally disintegrating "wafer", which rapidly dissolves in saliva. It is also available in 10-mg vials for intramuscular injection.[69]

Research

Olanzapine may be useful in promoting weight gain in underweight adult outpatients with anorexia nervosa. However, no improvement of psychological symptoms was noted.[126]

Olanzapine has been shown to be helpful in addressing a range of anxiety and depressive symptoms in individuals with schizophrenia and schizoaffective disorders, and has since been used in the treatment of a range of mood and anxiety disorders.[127] Olanzapine is no less effective than lithium or valproate and more effective than placebo in treating bipolar disorder.[128] It has also been used for Tourette syndrome and stuttering.[129]

Olanzapine has been studied for the treatment of hyperactivity, aggressive behavior, and repetitive behaviors in

autism.[130]

Olanzapine is frequently prescribed off-label for the treatment of insomnia, including difficulty falling asleep and staying asleep, even though such use is not recommended.[131] The daytime sedation experienced with olanzapine is generally comparable to quetiapine and lurasidone, which is a frequent complaint in clinical trials. In some cases, the sedation due to olanzapine impaired the ability of people to wake up at a consistent time every day. Some evidence of efficacy for treating insomnia is seen; however, side effects such as dyslipidemia and neutropenia, which may possibly be observed even at low doses, outweigh any potential benefits for insomnia that is not due to an underlying mental health condition.[132][133][134][135]

Olanzapine has been recommended to be used in antiemetic regimens in people receiving chemotherapy that has a high risk for vomiting.[136]

Olanzapine has been studied as an antiemetic, particularly for the control of chemotherapy-induced nausea and vomiting (CINV).[137]

In general, olanzapine appears to be about as effective as aprepitant for the prevention of CINV, though some concerns remain for its use in this population. For example, concomitant use of metoclopramide or haloperidol increases the risk for extrapyramidal symptoms. Otherwise, olanzapine appears to be fairly well tolerated for this indication, with somnolence being the most common side effect.[138]

Olanzapine has been considered as part of an

prodromal schizophrenia, who were at an estimated risk of 36–54% of developing schizophrenia within a year, and treated half with olanzapine and half with placebo.[139] In this study, patients receiving olanzapine did not have a significantly lower risk of progressing to psychosis (16.1% vs 37.9%). Olanzapine was effective for treating the prodromal symptoms, but was associated with significant weight gain.[140]

References

  1. ^ a b c "Drugs.com international listings for Olanzapine". Drugs.com. Retrieved 4 August 2015.
  2. FDA
    . Retrieved 22 October 2023.
  3. ^ Anvisa (31 March 2023). "RDC Nº 784 – Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 – Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  4. ^ "Zyprexa EPAR". European Medicines Agency. 27 September 1996. Retrieved 27 February 2024.
  5. PMID 9010634
    .
  6. PMID 10511917
    .
  7. S2CID 43859718
    .
  8. ^ a b c d e "PRODUCT INFORMATION OLANZAPINE SANDOZ® 2.5mg/5mg/7.5mg/10mg/15mg/20mg FILM-COATED TABLETS" (PDF). TGA eBusiness Services. Sandoz Pty Ltd. 8 June 2012. Retrieved 26 November 2013.
  9. ^ a b "Zyprexa, Zyprexa Relprevv (olanzapine) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 26 November 2013.
  10. ^ a b c d e f g h i j "Olanzapine, Olanzapine Pamoate Monograph for Professionals". Drugs.com. AHFS. Retrieved 24 December 2018.
  11. ISBN 978-1-118-75460-3
    .
  12. ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  13. ^ "Olanzapine – Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  14. ^ "FDA Approves Symbyax as First Medication for Treatment-Resistant Depression". Lilly. Eli Lilly. Retrieved 17 March 2021.
  15. hdl:10665/371090
    . WHO/MHP/HPS/EML/2023.02.
  16. PMID 30422498
    . Retrieved 20 November 2022.
  17. ^ "Olanzapine Indications: FDA-Approved Uses". psychopharmacologyinstitute.com. Retrieved 20 November 2022.
  18. ^ "FDA-Approved Drugs HIGHLIGHTS OF PRESCRIBING INFORMATION" (PDF). www.accessdata.fda.gov. Retrieved 20 November 2022.Public Domain This article incorporates text from this source, which is in the public domain.
  19. ^ "Olanzapine 10 mg Film-coated Tablets – Summary of Product Characteristics (SmPC) – (emc)". emc. Archived from the original on 20 November 2022. Retrieved 20 November 2022.
  20. ^ "Olanzapine AN Tablets". NPS MedicineWise. May 2018. Retrieved 20 November 2022.
  21. ^ "Overview | Psychosis and schizophrenia in adults: prevention and management | Guidance | NICE". www.nice.org.uk. 12 February 2014. Retrieved 30 November 2022.
  22. ^
    S2CID 32085212
    .
  23. ^
    S2CID 35702889
    .
  24. PMID 28219485
    .
  25. S2CID 22523977
    .
  26. PMID 15846619
    .
  27. PMID 20238348
    .
  28. ^ a b "Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care". NICE. 24 September 2014. Retrieved 26 July 2016.
  29. S2CID 199974
    .
  30. PMID 17156158
    .
  31. S2CID 34435730
    .
  32. PMID 24549862
    .
  33. ^ a b c Taylor D. The Maudsley prescribing guidelines in psychiatry. Wiley-Blackwell.
  34. PMID 18538144
    .
  35. PMID 23404872
    .
  36. ^ "Important Safety Information for Olanzapine". Zyprexa package insert. Eli Lilly & Company. 2007. Archived from the original on 23 November 2007. Retrieved 3 December 2007. Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. [...] ZYPREXA (olanzapine) is not approved for the treatment of elderly patients with dementia-related psychosis.
  37. ^ "Doctors 'ignoring drugs warning'". BBC News. 17 June 2008. Retrieved 22 June 2008.
  38. PMID 28540050
    .
  39. ^
    ISBN 978-1-59195-278-7
    .
  40. S2CID 80025501
    .
  41. ^ "Hyperprolactinaemia With Antipsychotics". www.medsafe.govt.nz. Retrieved 10 October 2022.
  42. ^ Joint Formulary Committee. "British National Formulary (online)". London: BMJ Group and Pharmaceutical. Retrieved 2 February 2020.
  43. S2CID 25016607
    .
  44. ^ "OLANZAPINE (olanzapine) tablet OLANZAPINE (olanzapine) tablet, orally disintegrating [Prasco Laboratories]". DailyMed. Prasco Laboratories. September 2013. Archived from the original on 5 July 2013. Retrieved 26 November 2013.
  45. ^ "Olanzapine 10 mg tablets – Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Aurobindo Pharma – Milpharm Ltd. 17 May 2013. Retrieved 26 November 2013.
  46. ^ "Olanzapine Monograph for Professionals - Drugs.com". Drugs.com. Retrieved 24 March 2017.
  47. S2CID 5965031
    .
  48. S2CID 24739534
    .
  49. ^ Moyer P (25 October 2005). "CAFE Study Shows Varying Benefits Among Atypical Antipsychotics". Medscape Medical News. WebMD. Retrieved 3 December 2007.
  50. ^ a b AstraZeneca Pharmaceuticals (4 April 2006). "Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomised Double Blind 52 Week Comparison". AstraZeneca Clinical Trials. AstraZeneca PLC. Archived from the original on 13 November 2007. Retrieved 3 December 2007. At week 12, the olanzapine-treated group had more weight gain, a higher increase in [ body mass index ], and a higher proportion of patients with a BMI increase of at least 1 unit compared with the quetiapine and risperidone groups (p<=0.01).
  51. PMID 10401912
    .
  52. ^ "NIMH study to guide treatment choices for schizophrenia" (Press release). National Institute of Mental Health. 19 September 2005. Retrieved 18 December 2006.
  53. PMID 17606657
    .
  54. PMID 9265916
    .
  55. S2CID 73047103
    .
  56. S2CID 22445875
    .
  57. PMID 17712347
    .
  58. PMID 14671184
    .
  59. ^ Carey B (20 September 2005). "Little Difference Found in Schizophrenia Drugs". The New York Times. Retrieved 3 December 2007.
  60. S2CID 38751442
    .
  61. ^
    S2CID 10928442
    .
  62. PMID 19410629
    .
  63. ISBN 978-0-85369-845-6
    . Withdrawal of antipsychotic drugs after long-term therapy should always be gradual and closely monitored to avoid the risk of acute withdrawal syndromes or rapid relapse.
  64. ^
    ISBN 978-0-19-852748-0
    .
  65. S2CID 6267180
    .
  66. ISBN 978-88-470-2679-7
    .
  67. ^ a b "Symbyax (Olanzapine and fluoxetine) drug overdose and contraindication information". RxList: The Internet Drug Index. WebMD. 2007. Archived from the original on 14 December 2007. Retrieved 3 December 2007.
  68. ^
    S2CID 21097041
    .
  69. ^ a b "Olanzapine Prescribing Information" (PDF). Eli Lilly and Company. 19 March 2009. Retrieved 6 September 2009.
  70. ^
    PMID 31564881
    .
  71. ^ a b c d e f g h i j k l m n o p q r s t u v w x Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
  72. ^
    PMID 18595716
    .
  73. ^
    PMID 12629531
    .
  74. ^
    S2CID 12028979
    .
  75. PMID 16314884
    .
  76. ^
    PMID 8997630
    .
  77. PMID 8632342
    .
  78. ^
    S2CID 19891653
    .
  79. ^
    S2CID 28536368
    .
  80. ^
    PMID 15771415
    .
  81. ^
    PMID 9577836
    .
  82. ^
    S2CID 2247093
    .
  83. ^
    PMID 8566176
    .
  84. PMID 9430133
    .
  85. PMID 9262370
    .
  86. ^
    PMID 8822531
    .
  87. PMID 10708730
    .
  88. PMID 12176106
    .
  89. ^ "NEJM Journal Watch: Summaries of and commentary on original medical and scientific articles from key medical journals". www.jwatch.org. Retrieved 27 November 2022.
  90. S2CID 23678989
    .
  91. S2CID 23678989
    .
  92. S2CID 19688114
    .
  93. S2CID 13365903
    .
  94. PMID 21843066
    .
  95. ^ Horn JR, Hansten P (1 December 2008). "Drug Transporters: The Final Frontier for Drug Interactions". Pharmacy Times. Archived from the original on 11 February 2017. Retrieved 9 February 2017.
  96. PMID 15855345
    .
  97. S2CID 5133679
    .
  98. PMID 16082416
    .
  99. ^ "olanzapine". NCI Drug Dictionary. National Cancer Institute. 2 February 2011.
  100. PMID 12650852
    .
  101. S2CID 19934754
    .
  102. ISBN 978-81-89960-30-8
    .
  103. PMID 23226055
    .
  104. PMID 33209310
    .
  105. ^ US patent 5817655, Chakrabarti JK, Hotten TM, Tupper DE, "Methods of treatment using a thieno-benzodiazepine", issued 1998-10-06, assigned to Eli Lilly and Co Ltd. 
  106. ^ "NDA 21–520" (PDF). Food and Drug Administration. 24 December 2003. Retrieved 6 September 2009.
  107. ^ "NDA 20-592 / S-019" (PDF). Food and Drug Administration. 14 January 2004. Retrieved 6 September 2009.
  108. PMID 22227765
    .
  109. PMID 19590732
    .
  110. ^ treatment resistant depression defined as major depressive disorder in adult patients who do not respond to two separate trials of different antidepressants of adequate dose and duration in the current episode
  111. ^ "NDA 20-592" (PDF). Food and Drug Administration. 6 September 1996. Retrieved 6 September 2009.
  112. ^ a b c d "Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations of Off-label Promotion of Zyprexa". U.S. Justice Department. 15 January 2009. Retrieved 9 July 2012.
  113. ^ "Lilly 2008 Annual Report" (PDF). Lilly. 2009. Archived from the original (PDF) on 1 October 2011. Retrieved 6 August 2009.
  114. ^ a b c d Walsh MW (5 September 2008). "Judge to Unseal Documents on the Eli Lilly Drug Zyprexa". The New York Times.
  115. ^ Berenson A (4 January 2007). "Mother Wonders if Psychosis Drug Helped Kill Son". The New York Times. Retrieved 21 May 2013.
  116. ^ a b c Berenson A (5 January 2007). "Lilly Settles With 18,000 Over Zyprexa". The New York Times.
  117. ^ a b c d Pagnamenta R (23 January 2007). "Eli Lilly was concerned by Zyprexa side-effects from 1998". The Times (London). Archived from the original on 20 February 2007.
  118. ^ Berenson A (17 December 2006). "Eli Lilly Said to Play Down Risk of Top Pill". The New York Times. Retrieved 21 May 2013.
  119. ^ Ashton K (16 January 2007). "Activist Gagged for Drug Fact Leak in Lily Case" (PDF). Hampshire Daily Gazette.
  120. ^ a b Harris G, Berenson A (14 January 2009). "Lilly Said to Be Near $1.4 Billion U.S. Settlement". The New York Times.
  121. ^ Berenson A (26 March 2008). "Lilly Settles Alaska Suit Over Zyprexa". The New York Times.
  122. ^ "Lilly settles Zyprexa suit for $1.42 billion". NBCNews.com. Associated Press. 15 January 2009. Archived from the original on 31 January 2021.
  123. ^ Berenson A (18 December 2006). "Drug Files Show Maker Promoted Unapproved Use". The New York Times. Retrieved 21 May 2013.
  124. ^ PsychRights (2010). Law Project for Psychiatric Rights: Summary and Links to Relevant Documents in the Zyprexa Scandal. PsychRights. Retrieved 26 October 2021.
  125. ^ Gottstein J (2021). The Zyreza Papers. Samizdat Health Writer's Cooperative 2021. Retrieved 26 October 2021.
  126. PMID 30654643
    .
  127. S2CID 23429449
    .
  128. PMID 19300587
    .
  129. ^ Scott L (Winter 2006). "Genetic and Neurological Factors in Stuttering". Stuttering Foundation of America.
  130. ^ "Olanzapine and Autism". Research Autism. 19 December 2017. Retrieved 9 June 2018.
  131. S2CID 10136993
    .
  132. doi:10.9740/mhc.n190091
    .
  133. S2CID 230507941
    .
  134. PMID 31860457
    .
  135. S2CID 195797603
    .
  136. PMID 28759346
    .
  137. PMID 30246876
    .
  138. PMID 29556812
    .
  139. S2CID 1118339
    .
  140. PMID 16648318
    .

External links

Wikimedia Commons has media related to Olanzapine.